(2-Butyloxiran-2-yl)methyl prop-2-enoate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2-Butyloxiran-2-yl)methyl prop-2-enoate
• 英文别名: (2-butyloxiran-2-yl)methyl prop-2-enoate
• 化学式: C₁₀H₁₆O₃
• 分子量: 184.23
• InChiKey: OHISGTHLEODISY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES AZOTÉS ET LEUR APPLICATION DANS DES MÉDICAMENTS
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2014012360A1

  公开（公告）日：2014-01-23

  The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

  本发明涉及医学领域，提供了新型含氮杂环化合物，其制备方法及其作为药物的用途，特别是用于治疗和预防组织纤维化。还提供了含有这些含氮杂环化合物的药用可接受的组合物，以及这些组合物在治疗人类或动物组织纤维化方面的用途，特别是用于人类或动物肾间质纤维化、肾小球硬化、肝纤维化、肺纤维化、腹膜纤维化、心肌纤维化、皮肤纤维化、术后粘连、良性前列腺增生、骨骼肌纤维化、硬皮病、多发性硬化、胰腺纤维化、肝硬化、肌肉瘤、神经纤维瘤、肺间质纤维化、糖尿病肾病、阿尔茨海默病或血管纤维化。
• Nitrogenous Heterocyclic Derivatives And Their Application In Drugs
  申请人：SUNSHINE LAKE PHARMA CO., LTD.

  公开号：US20150087639A1

  公开（公告）日：2015-03-26

  The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

  本发明涉及医学领域，提供了新颖的含氮杂环化合物，其制备方法及其作为药物的用途，特别是用于治疗和预防组织纤维化。还提供了包含这些含氮杂环化合物的药用组合物，以及这些组合物在治疗人类或动物组织纤维化方面的用途，特别是用于人类或动物肾间质纤维化、肾小球硬化、肝纤维化、肺纤维化、腹膜纤维化、心肌纤维化、皮肤纤维化、术后粘连、良性前列腺增生、骨骼肌纤维化、硬皮病、多发性硬化、胰腺纤维化、肝硬化、肌肉肉瘤、神经纤维瘤、肺间质纤维化、糖尿病肾病、阿尔茨海默病或血管纤维化。
• NITRILE-GROUP-CONTAINING COPOLYMER RUBBER, CROSSLINKABLE RUBBER COMPOSITION, AND CROSSLINKED RUBBER
  申请人：Zeon Corporation

  公开号：EP3176190A1

  公开（公告）日：2017-06-07

  A nitrile group-containing copolymer rubber containing α,β-ethylenically unsaturated nitrile monomer units in a ratio of 10 to 60 wt% and having a Z-average radius of gyration of 100 nm or more is provided. Preferably, the nitrile group-containing copolymer rubber of the present invention has an iodine value of 120 or less. Further, preferably, the nitrile group-containing copolymer rubber of the present invention has a plasticity number of 14 to 90. According to the present invention, it is possible to provide a nitrile group-containing copolymer rubber able to give a cross-linked rubber excellent in tensile stress, compression set resistance, and low heat buildup property.

  本发明提供了一种含腈基团的共聚橡胶，它含有α，β-乙烯基不饱和腈单体单元，其比例为 10 至 60 wt%，Z 平均回转半径为 100 nm 或更大。优选地，本发明的含腈基共聚橡胶的碘值为 120 或更低。此外，优选地，本发明的含腈基共聚橡胶的塑性数为 14 至 90。根据本发明，可以提供一种含腈基团的共聚橡胶，该橡胶能够提供一种在拉伸应力、抗压缩永久变形和低热积聚特性方面性能优异的交联橡胶。
• Compositions that can be vulcanized and that are based on ethylene/vinyl acetate copolymers containing epoxy groups
  申请人：Kalkofen Rainer

  公开号：US10100188B2

  公开（公告）日：2018-10-16

  The invention relates to vulcanizable compositions comprising (a) at least one ethylene-vinyl acetate copolymer containing epoxy groups and having a vinyl acetate content of at least 20% by weight, preferably at least 30% by weight, more preferably at least 40% by weight, based on the ethylene-vinyl acetate copolymer containing epoxy groups, and (b) at least one carboxylated nitrile rubber.

  本发明涉及可硫化组合物，其中包括 (a) 至少一种含有环氧基团的乙烯-醋酸乙烯共聚物，其醋酸乙烯酯含量至少为含环氧基团的乙烯-醋酸乙烯共聚物的 20%（按重量计），最好至少为 30%（按重量计），更理想的是至少为 40%（按重量计），以及 (b) 至少一种羧基丁腈橡胶。
• VULKANISIERBARE ZUSAMMENSETZUNGEN AUF BASIS EPOXYGRUPPEN-HALTIGER NITRILKAUTSCHUKE
  申请人：ARLANXEO Deutschland GmbH

  公开号：EP2658908B1

  公开（公告）日：2018-09-19